JP2018531962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531962A5 JP2018531962A5 JP2018521536A JP2018521536A JP2018531962A5 JP 2018531962 A5 JP2018531962 A5 JP 2018531962A5 JP 2018521536 A JP2018521536 A JP 2018521536A JP 2018521536 A JP2018521536 A JP 2018521536A JP 2018531962 A5 JP2018531962 A5 JP 2018531962A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable composition
- composition according
- dendrimer
- pamam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 25
- 239000000412 dendrimer Substances 0.000 claims description 15
- 229920000736 dendritic polymer Polymers 0.000 claims description 15
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 13
- 206010051606 Necrotising colitis Diseases 0.000 claims description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 8
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical compound NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003971 excitatory amino acid agent Substances 0.000 claims 1
- 239000004060 excitotoxin Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- -1 spacer compound Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229940039227 diagnostic agent Drugs 0.000 description 5
- 239000000032 diagnostic agent Substances 0.000 description 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- AHLWZBVXSWOPPL-RGYGYFBISA-N 20-deoxy-20-oxophorbol 12-myristate 13-acetate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(C=O)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C AHLWZBVXSWOPPL-RGYGYFBISA-N 0.000 description 1
- 206010058040 Abdominal sepsis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001602688 Pama Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110245A JP2022125314A (ja) | 2015-10-29 | 2022-07-08 | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248063P | 2015-10-29 | 2015-10-29 | |
| US62/248,063 | 2015-10-29 | ||
| PCT/US2016/058763 WO2017074993A1 (en) | 2015-10-29 | 2016-10-26 | Denderimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110245A Division JP2022125314A (ja) | 2015-10-29 | 2022-07-08 | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531962A JP2018531962A (ja) | 2018-11-01 |
| JP2018531962A5 true JP2018531962A5 (https=) | 2019-12-05 |
| JP7108306B2 JP7108306B2 (ja) | 2022-07-28 |
Family
ID=57286827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521536A Active JP7108306B2 (ja) | 2015-10-29 | 2016-10-26 | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
| JP2022110245A Pending JP2022125314A (ja) | 2015-10-29 | 2022-07-08 | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110245A Pending JP2022125314A (ja) | 2015-10-29 | 2022-07-08 | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170119897A1 (https=) |
| EP (1) | EP3368028B1 (https=) |
| JP (2) | JP7108306B2 (https=) |
| CN (1) | CN108289872B (https=) |
| AU (2) | AU2016346304B2 (https=) |
| CA (1) | CA3003628C (https=) |
| ES (1) | ES3012645T3 (https=) |
| WO (1) | WO2017074993A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
| CA2957721C (en) | 2014-08-13 | 2021-04-13 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| JP7108306B2 (ja) * | 2015-10-29 | 2022-07-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
| AU2018258654B2 (en) | 2017-04-27 | 2022-01-06 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
| WO2019005966A1 (en) * | 2017-06-29 | 2019-01-03 | Massachusetts Institute Of Technology | CONJUGATED DRUG DENDRIMER FOR EXTENDED INTRA-ARTICULAR ADMINISTRATION |
| EP3707193A1 (en) * | 2017-11-10 | 2020-09-16 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| WO2020146573A1 (en) * | 2019-01-09 | 2020-07-16 | The Johns Hopkins University | Compounds and treatments that enhance enteric nervous system function |
| JP7759322B2 (ja) | 2019-12-04 | 2025-10-23 | アシュバッタ セラピューティクス， インコーポレイテッド | 眼に薬物送達するためのデンドリマー組成物および方法 |
| EP4069307A2 (en) * | 2019-12-04 | 2022-10-12 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
| IL297531A (en) * | 2020-04-24 | 2022-12-01 | Ashvattha Therapeutics Inc | Dendrimer preparations and methods for treating severe acute respiratory distress syndrome |
| CA3189682A1 (en) * | 2020-07-17 | 2022-01-20 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to injured kidney |
| CN118948905A (zh) * | 2024-10-15 | 2024-11-15 | 杭州菌吾细研生物科技有限公司 | 植物乳植杆菌Mle-3应用及组合物和复合微生物制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030180250A1 (en) * | 2002-03-22 | 2003-09-25 | Council Of Scientific And Industrial Research | Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents |
| JP5484339B2 (ja) | 2007-10-05 | 2014-05-07 | ウェイン ステート ユニバーシティー | 合成物の持続的な放出のためのデンドリマー |
| WO2010147831A1 (en) | 2009-06-15 | 2010-12-23 | Wayne State University | Dendrimer based nanodevices for therapeutic and imaging purposes |
| EP2885318A4 (en) * | 2012-08-14 | 2016-03-30 | Angiochem Inc | PEPTIDE DENDRIMER CONJUGATES AND ITS USES |
| US20150352230A1 (en) * | 2013-01-11 | 2015-12-10 | The Regents Of The University Of Michigan | Synthesis and isolation of dendrimer based imaging systems |
| WO2015038493A1 (en) * | 2013-09-10 | 2015-03-19 | The Research Foundation For The State University Of New York | Synthesis of novel asymmetric bow-tie pamam dendrimer-based conjugates for tumor-targeting drug delivery |
| JP7108306B2 (ja) * | 2015-10-29 | 2022-07-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
-
2016
- 2016-10-26 JP JP2018521536A patent/JP7108306B2/ja active Active
- 2016-10-26 CA CA3003628A patent/CA3003628C/en active Active
- 2016-10-26 ES ES16794819T patent/ES3012645T3/es active Active
- 2016-10-26 WO PCT/US2016/058763 patent/WO2017074993A1/en not_active Ceased
- 2016-10-26 EP EP16794819.9A patent/EP3368028B1/en active Active
- 2016-10-26 AU AU2016346304A patent/AU2016346304B2/en active Active
- 2016-10-26 CN CN201680068854.0A patent/CN108289872B/zh active Active
- 2016-10-31 US US15/339,606 patent/US20170119897A1/en not_active Abandoned
-
2020
- 2020-01-08 AU AU2020200143A patent/AU2020200143B2/en active Active
-
2021
- 2021-09-24 US US17/484,175 patent/US20220080056A1/en not_active Abandoned
-
2022
- 2022-07-08 JP JP2022110245A patent/JP2022125314A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531962A5 (https=) | ||
| Das et al. | Codrug: An efficient approach for drug optimization | |
| CN104968368B (zh) | 固溶体组合物及其在剧痛中的用途 | |
| Bhosle et al. | Mutual Prodrug Concept: F Mutual Prodrug Concept: Fundamentals and undamentals and Applications | |
| JP6474352B2 (ja) | 慢性炎症及び炎症性疾患を治療する組成物と方法 | |
| RU2015117539A (ru) | Диагностика, профилактика и лечение болезней суставов | |
| JP2010502583A (ja) | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ | |
| SG183176A1 (en) | Treatment of respiratory disorders | |
| JP2010518122A5 (https=) | ||
| JP2018531962A (ja) | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 | |
| JP6462147B2 (ja) | Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用 | |
| IL144847A (en) | Compositions for the treatment of diseases related to the formation of blood vessels | |
| JP7436576B2 (ja) | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 | |
| Husain et al. | Prodrug rewards in medicinal chemistry: an advance and challenges approach for drug designing | |
| TW201105341A (en) | Pharmacetical composition for inhibitng pain | |
| JP2008533135A (ja) | ゲムシタビン誘導体の経口投薬形態 | |
| Pal et al. | Highly Efficient Prodrugs: Design and Therapeutic Applications (A-Review) | |
| CN105497019A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| CN113365617B (zh) | 用于医学疾病治疗的一氧化碳前药 | |
| KR20130040825A (ko) | 과황산화 글루코피라노사이드 | |
| WO2010103273A2 (en) | Essential fatty acid compounds | |
| JP2022503771A5 (https=) | ||
| JP2014530249A5 (https=) | ||
| ES2897576T3 (es) | Composiciones antimicrobianas con agentes efervescentes | |
| US20050227949A1 (en) | Compositions and methods for treatment of viral and bacterial infections |